MONISTAT
Pronunciation: mi-KON-a-zoel

What it isImidazole CYP51 inhibitor; cutaneous, vulvovaginal, and oropharyngeal fungal infections.
Why this oneIts topical, vaginal, and buccal formulations treat local disease with little systemic exposure.
What limits it⚑ Even vaginal or buccal use can potentiate warfarin enough to cause bleeding; local irritation is common.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Vaginal yeast infection | ≥12 yr | 1 applicatorful intravaginally QHS ×7 nights | ||
| External vulvar itching/irritation | ≥12 yr | apply to vulva BID ×up to 7 days PRN |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Undefined
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 2 % | cream | per unit | not offered | |
| 4 % | cream | per unit | not offered | |
| 100 mg | supp | per unit | not offered | |
| 200 mg | supp | per unit | $13.89/ea | offered |
Generic entry1992
NO BOXED WARNINGS
Principal riskEven topical forms raise warfarin enough to cause bleeding
Legacy pregnancy categoryC
Defining liabilityLocal irritation or hypersensitivity; systemic toxicity is minimal with correct local use.